Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
Seyed Fazel Nabavi, Solomon Habtemariam, Emilio Clementi, Ioana Berindan‐Neagoe, Cosmin Andrei Cismaru, Mahsa Rasekhian, Maciej Banach, Morteza Izadi, Mahdi Bagheri, Mohammad Sadegh Bagheri, Seyed Mohammad Nabavi
Abstract
1. Wang LS, Wang YR, Ye DW, Liu QQ. (2020). A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence Int J Antimicrob Agents. : 105948. doi:10.1016/j.ijantimicag.2020.105948. CrossRef Google Scholar
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyCoronavirusPandemicSars virusMedicineInfectious disease (medical specialty)OutbreakInternal medicineDiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCancer Immunotherapy and Biomarkers